MX2009012000A - Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis. - Google Patents

Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.

Info

Publication number
MX2009012000A
MX2009012000A MX2009012000A MX2009012000A MX2009012000A MX 2009012000 A MX2009012000 A MX 2009012000A MX 2009012000 A MX2009012000 A MX 2009012000A MX 2009012000 A MX2009012000 A MX 2009012000A MX 2009012000 A MX2009012000 A MX 2009012000A
Authority
MX
Mexico
Prior art keywords
angiogenesis
hif
inhibitors
useful
diseases associated
Prior art date
Application number
MX2009012000A
Other languages
English (en)
Inventor
Michael Haerter
Karl-Heinz Thierauch
Peter Ellinghaus
Hartmut Beck
Stephen Boyer
Philip Wickens
Manoj Patel
Ellalahewage Sathyajith Kumarasinghe
Ajay Kumar Bhargava
Susanne Greschat
Patrick Paulus
Holger Hess-Stumpp
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2009012000A publication Critical patent/MX2009012000A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a nuevos compuestos de pirazol heteroarilo sustituidos, a composiciones farmacéuticas que contienen esos compuestos y al uso de esos compuestos o composiciones para el tratamiento de trastornos hiperproliferativos y/o de la angiogénesis, como agente único o en combinación con otros principios activos o medidas terapéuticas.
MX2009012000A 2007-05-18 2008-05-08 Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis. MX2009012000A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93081607P 2007-05-18 2007-05-18
PCT/EP2008/003681 WO2008141731A2 (en) 2007-05-18 2008-05-08 Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Publications (1)

Publication Number Publication Date
MX2009012000A true MX2009012000A (es) 2009-11-19

Family

ID=39760483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012000A MX2009012000A (es) 2007-05-18 2008-05-08 Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.

Country Status (19)

Country Link
US (1) US8796253B2 (es)
EP (1) EP2148877A2 (es)
JP (1) JP5702138B2 (es)
KR (1) KR20100016617A (es)
CN (1) CN101765596B (es)
AR (1) AR066617A1 (es)
AU (1) AU2008253311A1 (es)
BR (1) BRPI0812361A2 (es)
CA (1) CA2687306A1 (es)
CL (1) CL2008001372A1 (es)
IL (1) IL201537A0 (es)
MX (1) MX2009012000A (es)
PA (1) PA8780201A1 (es)
PE (1) PE20090297A1 (es)
RU (1) RU2009146851A (es)
TW (1) TW200909428A (es)
UY (1) UY31080A1 (es)
WO (1) WO2008141731A2 (es)
ZA (1) ZA200907999B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
PL2356113T3 (pl) * 2008-11-14 2015-06-30 Bayer Ip Gmbh Heterocyklicznie podstawione związki arylowe jako inhibitory HIF
MX2011004779A (es) * 2008-11-14 2011-05-30 Bayer Schering Pharma Ag Compuestos de arilo sustituido y su uso como inhibidores de hif.
MX2011007054A (es) 2008-12-29 2011-11-29 Sanofi Sa Derivados de 2-il-pirazol-3(2h)-ona, su preparacion y su aplicacion en terapeutica como activadores de hif.
CA2748413A1 (fr) 2008-12-29 2010-07-08 Sanofi Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
WO2010085584A1 (en) * 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
US8242284B1 (en) * 2009-09-21 2012-08-14 The United States Of America As Represented By The United States Department Of Energy Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making
US8680098B2 (en) * 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
CN101805338B (zh) * 2010-04-06 2014-10-15 沈阳药科大学 噁二唑基哌嗪衍生物及其用途
EP2560969B1 (en) * 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
EA201291167A1 (ru) 2010-05-08 2013-05-30 Байер Интеллектуэль Проперти Гмбх Замещенные гетероциклилбензилпиразолы и их применение
JP2013530139A (ja) 2010-05-08 2013-07-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒドロキシアルキルベンジルピラゾール類およびその使用
EP2390252A1 (en) * 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
EA026692B1 (ru) 2010-06-30 2017-05-31 Айронвуд Фармасьютикелз, Инк. Стимуляторы sgc
WO2012064559A1 (en) 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
NO2686520T3 (es) 2011-06-06 2018-03-17
MX2013014310A (es) * 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
HK1203946A1 (en) 2011-10-17 2015-11-06 Bayer Intellectual Property Gmbh Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
WO2014031933A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
JP6453218B2 (ja) 2012-08-24 2019-01-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 疾患を治療するためのｈｉｆ活性の複素環式修飾物質
WO2014031928A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
CN104968667B (zh) * 2013-02-05 2017-06-20 山东轩竹医药科技有限公司 四并环激酶抑制剂
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
US20150105252A1 (en) * 2013-10-15 2015-04-16 E I Du Pont De Nemours And Company Substituted pyrazoles as herbicides
EP3110420B8 (en) 2014-02-25 2019-07-10 Board of Regents, The University of Texas System Salts of heterocyclic modulators of hif activity for treatment of disease
CR20170100A (es) 2014-09-19 2017-04-24 Bayer Pharma Aktiengesellchaft Indazoles sustituidos con bencilo como inhibidores bub1
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EA036920B1 (ru) 2015-04-01 2021-01-15 Экебиа Терапьютикс, Инк. Композиции и способы для лечения анемии
CN106366078A (zh) * 2015-07-24 2017-02-01 浙江大学 吲唑-噁二唑类衍生物、含其的药物组合物及其在抗肿瘤中的应用
WO2017039318A1 (en) * 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
CN108164520B (zh) * 2018-01-15 2021-03-19 东南大学 缺氧抑制剂与抗肿瘤药物的偶联化合物及其制备和应用
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110257393A (zh) * 2019-06-28 2019-09-20 西安医学院 翻译后水平低氧调控基因、应用及其调控方法
CN112110908A (zh) * 2020-09-25 2020-12-22 山东大学 一种1,3-二取代吲唑类化合物及其制备方法和应用
CN112426422A (zh) * 2020-12-02 2021-03-02 安徽医科大学 吡啶甲酰胺衍生物AMSP-30m在制备防治类风湿关节炎药物中的应用
WO2022131146A1 (ja) * 2020-12-17 2022-06-23 国立大学法人京都大学 含窒素複素環式化合物
WO2024067708A1 (zh) * 2022-09-30 2024-04-04 苏州阿尔脉生物科技有限公司 草酸胺类衍生物、包含其的药物组合物及其医药用途
CN117800894A (zh) * 2022-09-30 2024-04-02 苏州阿尔脉生物科技有限公司 饱和环类衍生物、包含其的药物组合物及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
JP3729343B2 (ja) * 2000-04-27 2005-12-21 アステラス製薬株式会社 縮合ヘテロアリール誘導体
KR20040004705A (ko) 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤
WO2004058176A2 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CA2530679A1 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds for treating angiogenesis
US8329703B2 (en) 2005-02-15 2012-12-11 Xtl Biopharmaceuticals Ltd. Pyrazole compounds
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
JP5237799B2 (ja) * 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EA201291167A1 (ru) * 2010-05-08 2013-05-30 Байер Интеллектуэль Проперти Гмбх Замещенные гетероциклилбензилпиразолы и их применение

Also Published As

Publication number Publication date
RU2009146851A (ru) 2011-06-27
TW200909428A (en) 2009-03-01
JP5702138B2 (ja) 2015-04-15
CN101765596B (zh) 2015-04-29
IL201537A0 (en) 2010-05-31
PA8780201A1 (es) 2009-02-09
CL2008001372A1 (es) 2008-12-05
CA2687306A1 (en) 2008-11-27
AR066617A1 (es) 2009-09-02
KR20100016617A (ko) 2010-02-12
EP2148877A2 (en) 2010-02-03
WO2008141731A3 (en) 2009-03-26
WO2008141731A2 (en) 2008-11-27
UY31080A1 (es) 2009-01-05
CN101765596A (zh) 2010-06-30
JP2010527378A (ja) 2010-08-12
PE20090297A1 (es) 2009-03-27
BRPI0812361A2 (pt) 2015-02-03
US8796253B2 (en) 2014-08-05
ZA200907999B (en) 2011-06-29
AU2008253311A1 (en) 2008-11-27
US20100249085A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
MX2009012000A (es) Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2008012490A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
MX2015011799A (es) (bencil-ciano-metil)-amidas del acido 2-aza-biciclo[2.2.1]heptano- 3-carboxilico sustituidas como inhibidores de catepsina c.
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
ATE520668T1 (de) Sigmarezeptor-inhibitoren
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
WO2010051935A3 (en) Substituted amido phenoxybenzamides

Legal Events

Date Code Title Description
FA Abandonment or withdrawal